MAGNETIC RESONANCE IMAGING IN DIAGNOSIS, STAGING AND RADIOTHERAPY PLANNING FOR PROSTATE CANCER

REFERENCES

• Fuchsjager M, Shukla-Dave A, Akin O, Barentsz J, Hricak H. Prostate can-cer imaging. Acta Radiol 2008; 49:107–120.
   PubMed Web of Science ®Google Scholar
• Villeirs GM, De Meerleer GO. Magnetic resonance imaging (MRI) anat-omy of the prostate and application of MRI in radiotherapy planning. Eur J Radiol 2007; 63:361–368.
   PubMed Web of Science ®Google Scholar
• Coakley F, Hricak H. Radiologic anatomy of the prostate gland: a clini-cal approach. Radiol din North Am 2000; 38:15–30.
   PubMed Web of Science ®Google Scholar
• Janus C, Lippert M. Benign prostatic hyperplasia: appearance on mag-netic resonance imaging. Urology 1992; 40:539–541.
   PubMed Web of Science ®Google Scholar
• Villeirs GM, Oosterlinck W, Vanherreweghe E, De Meerleer GO. A qualita-tive approach to combined magnetic resonance imaging and spectros-copy in the diagnosis of prostate cancer. Eur J Radiol 2010; 73:352–356.
   PubMed Web of Science ®Google Scholar
• McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and di-rection of spread. Am J Surg Pathol 1988; 12:897–906.
   PubMed Web of Science ®Google Scholar
• Li H, Sugimura K, Kaji Y, et al. Conventional MRI capabilities in the di-agnosis of prostate cancer in the transition zone. AJR Am J Roentgenol 2006; 186:729–742.
   PubMed Web of Science ®Google Scholar
• Beyersdorff D, Taupitz M, Winkelmann B, et al. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology 2002; 224:701–706.
   PubMed Web of Science ®Google Scholar
• Casciani E, Polettini E, Bertini L, et al. Contribution of the MR spectro-scopic imaging in the diagnosis of prostate cancer in the peripheral zone. Abdom Imaging 2007; 32:796–802.
   PubMed Web of Science ®Google Scholar
• Perrotti M, Han KR, Epstein RE, et al. Prospective evaluation of endorec-tal magnetic resonance imaging to detect tumor foci in men with prior negative prostastic biopsy: a pilot study.J Urol 1999; 162: 1314–1317.
   PubMed Web of Science ®Google Scholar
• Prando A, Kurhanewicz J, Borges AP, Oliveira EM, Jr., Figueiredo E. Pros-tatic biopsy directed with endorectal MR spectroscopic imaging find-ings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 2005; 236: 903–910.
   PubMed Web of Science ®Google Scholar
• Vilanova JC, Comet J, Capdevila A, et al. The value of endorectal MR imaging to predict positive biopsies in clinically intermediate-risk pros-tate cancer patients. Eur Radiol 2001; 11:229–235.
   PubMed Web of Science ®Google Scholar
• Yuen JS, Thng CH, Tan PH, et al. Endorectal magnetic resonance im-aging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy.J Urol 2004; 171: 1482–1486.
   PubMed Web of Science ®Google Scholar
• Kim CK, Park BK. Update of prostate magnetic resonance imaging at 3 T. J Comput Assist Tomogr 2008; 32: 163–172.
   PubMed Web of Science ®Google Scholar
• Morakkabati-Spitz N, Bastian PJ, Gieseke J, et al. MR imaging of the prostate at 3.0T with external phased array coil - preliminary results. Eur J Med Res 2008; 13:287–291.
   PubMed Web of Science ®Google Scholar
• Jung JA, Coakley FV, Vigneron DB, et al. Prostate depiction at endorec-tal MR spectroscopic imaging: investigation of a standardized evalua-tion system. Radiology 2004; 233: 701–708.
   PubMed Web of Science ®Google Scholar
• Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinico-pathologic study. Radiology 1999; 213:473–480.
   PubMed Web of Science ®Google Scholar
• Testa C, Schiavina R, Lodi R, et al. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiol-ogy 2007; 244: 797–806.
   PubMed Web of Science ®Google Scholar
• Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000; 164:400–404.
   PubMed Web of Science ®Google Scholar
• Westphalen AC, Coakley FV, Qayyum A, et al. Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. Radiology 2008; 246:177–184.
   PubMed Web of Science ®Google Scholar
• Seitz M, Shukla-Dave A, Bjartell A, et al. Functional magnetic resonance imaging in prostate cancer. Eur Urol 2009; 55: 801–814.
   PubMed Web of Science ®Google Scholar
• Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer local-ization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006; 241:449–458.
   PubMed Web of Science ®Google Scholar
• Kurhanewicz J, Vigneron DB. Advances in MR spectroscopy of the pros-tate. Magn Reson Imaging din N Am 2008; 16:697–710, ix-x.
   PubMed Web of Science ®Google Scholar
• Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectro-scopic imaging with Gleason score based on step-section pathologic analasis after radical prostatectomy. Radiology 2005; 234:804–814.
   PubMed Web of Science ®Google Scholar
• Villeirs GM, De Meerleer GO, De Visschere P J, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spec-troscopy in the assessment of high grade prostate carcinoma in pa-tients with elevated PSA: A single-institution experience of 356 pa-tients. Eur J Radiol 2009. [Epub ahead of print]
   Web of Science ®Google Scholar
• McMahon CJ, Bloch BN, Lenkinski RE, Rofsky NM. Dynamic contrast-enhanced MR imaging in the evaluation of patients with prostate can-cer. Magn Reson Imaging din N Am 2009; 17:363–383.
   PubMed Web of Science ®Google Scholar
• Ocak I, Bernardo M, Metzger G, et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AIR Am J Roentgenol 2007; 189:849.
   PubMed Web of Science ®Google Scholar
• Somford DM, Futterer J J, Hambrock T, Barentsz JO. Diffusion and perfu-sion MR imaging of the prostate. Magn Reson Imaging din N Am 2008; 16: 685–695, ix.
   PubMed Web of Science ®Google Scholar
• Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H. MR imaging of the prostate in clinical practice. Magma 2008; 21:379–392.
   PubMedGoogle Scholar
• Sato C, Naganawa S, Nakamura T, et al. Differentiation of noncancer-ous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate.J Magn Reson Imag-ing 2005; 21:258–262.
   PubMed Web of Science ®Google Scholar
• desouza NM, Reinsberg SA, Scurr ED, Brewster JM, Payne GS. Magnetic resonance imaging in prostate cancer: the value of apparent diffusion coefficients for identifying malignant nodules. Br J Radio/ 2007; 80:90–95.
   PubMed Web of Science ®Google Scholar
• Van As N, Charles-Edwards E, Jackson A, et al. Correlation of diffusion-weighted MRI with whole mount radical prostatectomy specimens. Br J Radiol 2008; 81:456–462.
   PubMed Web of Science ®Google Scholar
• Yoshimitsu K, Kiyoshima K, Irie H, et al. Usefulness of apparent dif-fusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. J Magn Reson Imaging 2008; 27: 132–139.
   PubMed Web of Science ®Google Scholar
• Chen M, Dang HD, Wang JY, et al. Prostate cancer detection: com-parison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol 2008; 49:602–610.
   PubMed Web of Science ®Google Scholar
• Heidenreich AA us G, Bolla M, et al. EAU Guidelines on Prostate Cancer. Eur Urol 2008; 53:68–80.
   PubMed Web of Science ®Google Scholar
• Ayala A, Ro J, Babaian R, Troncoso P, Grignon D. The prostatic capsule: does it exist? Its importance in the staging and treatment of prostatic carcinoma. Am J Surg Pathol 1989; 13:21–27.
   PubMed Web of Science ®Google Scholar
• van der Kwast TH, Collette L, Van Poppel H, et al. Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911). Virchows Arch 2006; 449:428–434.
   PubMed Web of Science ®Google Scholar
• Outwater EK, Petersen RO, Siegelman ES, Gomella LG, Chernesky CE, Mitchell DG. Prostate carcinoma: assessment of diagnostic criteria for capsular penetration on endorectal coil MR images. Radiology 1994; 193:333–339.
   PubMed Web of Science ®Google Scholar
• Yu K, Hricak H, Alagappan R, Chernoff D, Bacchetti P, Zaloudek C. De-tection of extracapsular extension of prostate carcinoma with en-dorectal and phased-array coil MR imaging: multivariate feature analy-sis. Radiology 1997; 202:697–702.
   PubMed Web of Science ®Google Scholar
• Bartolozzi C, Menchi I, Lencioni R, et al. Local staging of prostate carci-noma with endorectal coil MRI: correlation with whole-mount radical prostatectomy specimens. Eur Radiol 1996; 6:339–345.
   PubMed Web of Science ®Google Scholar
• Rorvik J, Halvorsen OJ, Albrektsen G, Ersland L, Daehlin L, Haukaas S. MRI with an endorectal coil for staging of clinically localised prostate cancer prior to radical prostatectomy. Eur Radiol 1999; 9:29–34.
   PubMed Web of Science ®Google Scholar
• Yu KK, Scheidler J, Hricak H, et al. Prostate cancer: prediction of extra-capsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999; 213:481–488.
   PubMed Web of Science ®Google Scholar
• Sala E, Akin O, Moskowitz CS, et al. Endorectal MR imaging in the evalu-ation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology 2006; 238:929–937.
   PubMed Web of Science ®Google Scholar
• De Meerleer G,Villeirs G, Bral S, et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of inten-sity-modulated radiotherapy. Radiother Oncol 2005; 75:325–333.
   PubMed Web of Science ®Google Scholar
• Pickett B,Vigneault E, Kurhanewicz J, Verhey L, Roach M. Static field in-tensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Intl RadiatOncol Biol Phys 1999; 44:921–929.
   PubMed Web of Science ®Google Scholar
• Villeirs GM, Van Vaerenbergh K, Vakaet L, et al. Interobserver delinea-tion variation using CT versus combined CT + MRI in intensity-modu-lated radiotherapy for prostate cancer. Strahlenther Onkol 2005; 181: 424–430.
   PubMed Web of Science ®Google Scholar
• Cellini N, Morganti AG, Mattiucci GC, et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Intl Radiat Oncol Biol Phys 2002; 53: 595–599.
   PubMed Web of Science ®Google Scholar
• Hanks GE, Hanlon AL, Schultheiss TE, et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. int J Radiat Oncol Biol Phys 1998; 41: 501–510.
   PubMed Web of Science ®Google Scholar
• Michalski JM, Winter K, Purdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Intl Radiat Oncol Biol Phys 2004; 58: 735–742.
   PubMed Web of Science ®Google Scholar
• Ryu JK, Winter K, Michalski JM, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/ RTOG 9406, level III (79.2 Gy). Intl Radiat Oncol Biol Phys 2002; 54: 1036–1046.
   PubMed Web of Science ®Google Scholar